Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy

BMC Cancer

Volumn 9, Issue , 2009, Pages 352-

  Casula, Milena ^a   Muggiano, Antonio ^b   Cossu, Antonio ^c   Budroni, Mario ^d   Caracò, Corrado ^e   Ascierto, Paolo A ^e   Pagani, Elena ^f   Stanganelli, Ignazio ^g   Canzanella, Sergio ^h   Sini, MariaCristina ^a   Palomba, Grazia ^a   Palmieri, Giuseppe ^a  

^a CNR   (Italy)

^b Ospedale Oncologico A Businco   (Italy)

^c UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^d Servizio Epidemiologia   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^g Istituto Tumori della Romagna   (Italy)

^h Associazione House Hospital Onlus   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRCA2 PROTEIN; CELL PROTEIN; GENOMIC DNA; MELANOCORTIN 1 RECEPTOR; PROTEIN P16CDKN2A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA SEQUENCE; ENZYME ACTIVATION; ETHNIC DIFFERENCE; FEMALE; GENE SILENCING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; GERM LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE N RAS; REGULATOR GENE; SEQUENCE ANALYSIS; SOMATIC MUTATION;

EID: 70449512620     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-352     Document Type: Article

References (41)

1. de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. BMJ 2005, 331:698. 10.1136/bmj.331.7518.698, 1226263, 16179724.
2. Lipsker D, Engel F, Cribier B, Velten M, Hedelin G. Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol 2007, 157:338-343. 10.1111/j.1365-2133.2007.08029.x, 17596175.
3. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005, 331:481. 10.1136/bmj.38516.649537.E0, 1199022, 16081427.
4. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1969-1997 rising trends in incidence and mortality, but recent stabilisations in western Europe and decreases in Scandinavia. Int J Cancer 2003, 107:119-126. 10.1002/ijc.11360, 12925966.
5. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, . eds Cancer Incidence in Five Continents. 2007, IX. International Agency for Research on Cancer (IARC) Scientific Publications, No. 160 Lyon, IARC.
6. Bataille V. Genetic epidemiology of melanoma. Eur J Cancer 2003, 39:1341-1347. 10.1016/S0959-8049(03)00313-7, 12826035.
7. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003, 22:3099-3112. 10.1038/sj.onc.1206450, 12789287.
8. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. The Lancet 2005, 365:687-701.
9. Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005, 23:2669-2675. 10.1200/JCO.2005.11.108, 15837981.
10. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA, . Melanoma Genetics Consortium Geographical variation in penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002, 94:894-903.
11. Casula M, Colombino M, Satta MP, Cossu A, Lissia A, Budroni M, Simeone E, Calemma R, Loddo C, Caracò C, Mozzillo N, Daponte A, Comella G, Canzanella S, Guida M, Castello G, Ascierto PA, Palmieri G. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer 2007, 43:137-143. 10.1016/j.ejca.2006.07.017, 17055252.
12. The Breast Cancer Linkage Consortium Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91:1310-1316. 10.1093/jnci/91.15.1310, 10433620.
13. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004, 22:735-742. 10.1200/JCO.2004.05.055, 14966099.
14. Sinilnikova OM, Egan KM, Quinn JL, Boutrand L, Lenoir GM, Stoppa-Lyonnet D, Desjardins L, Levy C, Goldgar D, Gragoudas ES. Germline BRCA2 sequence variants in patients with ocular melanoma. Int J Cancer 1999, 82:325-328. 10.1002/(SICI)1097-0215(19990730)82:3<325::AID-IJC3>3.0.CO;2-G, 10399947.
15. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001, 117:294-300. 10.1046/j.0022-202x.2001.01421.x, 11511307.
16. Debniak T, Scott RJ, Górski B, Cybulski C, Wetering T, Serrano-Fernandez P, Huzarski T, Byrski T, Nagay L, Debniak B, Kowalska E, Jakubowska A, Gronwald J, Wokolorczyk D, Maleszka R, Kładny J, Lubinski J. Common variants of DNA repair genes and malignant melanoma. Eur J Cancer 2008, 44:110-114. 10.1016/j.ejca.2007.10.006, 18024013.
17. Beaumont KA, Shekar SN, Newton RA, James MR, Stow JL, Duffy DL, Sturm RA. Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet 2007, 16:2249-2260. 10.1093/hmg/ddm177, 17616515.
18. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008, 122:2753-2760. 10.1002/ijc.23396, 18366057.
19. Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Busam K, From L, Mujumdar U, Wilcox H, Begg CB, Berwick M. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res 2006, 66:9330-9337. 10.1158/0008-5472.CAN-06-1634, 16982779.
20. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006, 313:521-522. 10.1126/science.1127515, 16809487.
21. Box NF, Duffy DL, Irving RE, Russell A, Chen W, Griffyths LR, Parsons PG, Green AC, Sturm RA. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol 2001, 116:224-229. 10.1046/j.1523-1747.2001.01224.x, 11179997.
22. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147. 10.1056/NEJMoa050092, 16291983.
23. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60:1800-1804.
24. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 2006, 25:3357-3364. 10.1038/sj.onc.1209379, 16462768.
25. Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A. Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med 2007, 11:1052-1068. 10.1111/j.1582-4934.2007.00091.x, 17979882.
26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho J, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
27. Smalley KSM. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer 2003, 104:527-532. 10.1002/ijc.10978, 12594806.
28. Palomba G, Pisano M, Cossu A, Budroni M, Dedola MF, Farris A, Contu A, Baldinu P, Tanda F, Palmieri G. Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian breast cancer patients through a hospital-based screening. Cancer 2005, 104:1172-1179. 10.1002/cncr.21298, 16047344.
29. Budroni M, Cesaraccio R, Coviello V, Sechi O, Pirino D, Cossu A, Tanda F, Pisano M, Palomba G, Palmieri G. Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer 2009, 9:62. 10.1186/1471-2407-9-62, 2653541, 19232099.
30. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003, 22:3053-3062. 10.1038/sj.onc.1206445, 12789280.
31. Wolchok JD, Saenger YM. Current topics in melanoma. Curr Opin Oncol 2007, 19:116-120. 10.1097/CCO.0b013e32801497c6, 17272983.
32. Casula M, Ascierto PA, Cossu A, Sini MC, Tore S, Colombino M, Satta MP, Manca A, Rozzo C, Satriano SMR, Castello G, Lissia A, Tanda F, Palmieri G. Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9p21. Melanoma Res 2003, 13:571-579. 10.1097/00008390-200312000-00006, 14646620.
33. Wright AF, Carothers AD, Pirastu M. Population choice in mapping genes for complex diseases. Nat Genet 1999, 23:397-404. 10.1038/70501, 10581024.
34. Palomba G, Cossu A, Friedman E, Budroni M, Farris A, Contu A, Pisano M, Baldinu P, Sini MC, Tanda F, Palmieri G. Origin and distribution of the BRCA2-8765delAG mutation in breast cancer. BMC Cancer 2007, 7:132. 10.1186/1471-2407-7-132, 1940259, 17640379.
35. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?. Am J Hum Genet 2000, 66:176-186. 10.1086/302711, 1288324, 10631149.
36. Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, Swoyer J, Ter-Minassian M, Hedayati M, Grossman L, Goldstein AM, Calista D, Pfeiffer RM. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005, 97:998-1007.
37. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006, 126:154-160. 10.1038/sj.jid.5700026, 16417231.
38. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006, 12:2301-2307.
39. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33:19-20. 10.1038/ng1054, 12447372.
40. McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003, 98:1223-1231. 10.1002/cncr.11624, 12973846.
41. Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007, 25:1129-1134. 10.1200/JCO.2006.08.1463, 17369575.